SCHEMBL19209909

SCHEMBL19209909

CS(=O)(=O)O[C@H]1CCCN(Cc2ccccc2)C1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.58
ALDH1A1 P00352 2/20 0.57
MAOB P27338 2/20 0.56
CYP2D6 P10635 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C19 P33261 1/20 0.54
HRH3 Q9Y5N1 1/20 0.49
KDM4E B2RXH2 2/20 0.49
ROCK1 Q13464 3/20 0.48
ROCK2 O75116 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CCR2 P41597 1/20 0.47
HPGD P15428 1/20 0.47
ACHE P22303 1/20 0.46
RECQL P46063 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5745231 1.00 BCHE (0.58) BCHEALDH1A1MAOBCYP2D6CYP1A2
SCHEMBL28497475 1.00 BCHE (0.58) BCHEALDH1A1MAOBCYP2D6CYP1A2
SCHEMBL608203 0.92 SMN1; SMN2 (0.51) BCHEALDH1A1MAOBCYP2D6CYP1A2
SCHEMBL3273941 0.92 SMN1; SMN2 (0.51) BCHEALDH1A1MAOBCYP2D6CYP1A2
SCHEMBL608204 0.92 SMN1; SMN2 (0.51) BCHEALDH1A1MAOBCYP2D6CYP1A2
SCHEMBL6279418 0.86 ALDH1A1 (0.57) BCHEALDH1A1MAOBHRH3ACHE
SCHEMBL5746137 0.86 FUCA1 (0.47) BCHEMAOBCYP2D6HRH3ACHE
SCHEMBL5744278 0.83 HRH3 (0.59) BCHEALDH1A1HRH3ACHERECQL
SCHEMBL28508903 0.83 BCHE (0.52) BCHEALDH1A1MAOBCYP2D6CYP1A2
SCHEMBL5743312 0.83 BCHE (0.52) BCHEALDH1A1MAOBCYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10435409-B2 Process for the preparation of ibrutinib SHILPA MEDICARE LIMITED 2019-10-08 US claimed
US-20190040069-A1 PROCESS FOR THE PREPARATION OF IBRUTINIB SHILPA MEDICARE LIMITED (IN) 2019-02-07 US claimed
US-10435409-B2 Process for the preparation of ibrutinib SHILPA MEDICARE LIMITED 2019-10-08 US disclosed
US-10435409-B2 Process for the preparation of ibrutinib SHILPA MEDICARE LIMITED 2019-10-08 US disclosed
US-20190040069-A1 PROCESS FOR THE PREPARATION OF IBRUTINIB SHILPA MEDICARE LIMITED (IN) 2019-02-07 US disclosed
US-20190040069-A1 PROCESS FOR THE PREPARATION OF IBRUTINIB SHILPA MEDICARE LIMITED (IN) 2019-02-07 US disclosed
WO-2017134588-A1 PROCESS FOR THE PREPARATION OF IBRUTINIB SHILPA MEDICARE LIMITED (IN) 2017-08-10 WO disclosed
WO-2017134588-A1 PROCESS FOR THE PREPARATION OF IBRUTINIB SHILPA MEDICARE LIMITED (IN) 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190040069-A1 PROCESS FOR THE PREPARATION OF IBRUTINIB BTK, SYK, JAK1 BCHE 4742/4885ALDH1A1 594/4885MAOB 3370/4885
US-10435409-B2 Process for the preparation of ibrutinib BTK, SYK, JAK1 BCHE 4750/4885ALDH1A1 534/4885MAOB 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.